Amin, Neeta B.
Pfizer (United States)
3 papers on CoChatORCID 0000-0002-0727-4683
Most cited papers
- Verified
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine
Liver Disease Diagnosis and TreatmentLipid metabolism and disorders
Cited by 219
- Verified
Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
Amin, N. B., Wang, X., Mitchell, J. R., Lee, D. S., Nucci, G., & Rusnak, J. M. (2015) · Diabetes, Obesity and Metabolism
Blood Pressure and Hypertension StudiesDiabetes Treatment and Management
Cited by 60
- Verified
Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology
Amin, N. B., Saxena, A. R., Somayaji, V., & Dullea, R. (2023) · Clinical Therapeutics
Liver Disease Diagnosis and TreatmentLipid metabolism and biosynthesis
Cited by 48
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free